N/A
N=10
Cardiac Magnetic Resonance Imaging in Patients With Non-Hodgkin Lymphoma or Hodgkin Lymphoma Receiving Doxorubicin
Cardiac Toxicity · Chemotherapeutic Agent Toxicity · Lymphoma
Bottom Line
View on ClinicalTrials.gov: NCT00577798 ↗Enrolled (actual)
10
Serious AEs
0.0%
Results posted
Nov 2023
Primary outcome: Primary: Left Ventricular Ejection Fraction (LVEF) and Global Strain Decrease After Doxorubicin Chemotherapy — 5; 5 Participants
Study Design & Population
- Study type
- Observational
- Phase
- N/A
- Interventions
- contrast-enhanced magnetic resonance imaging (Procedure)
- Age
- Adult, Older Adult · 19+ yrs
- Sex
- All
- Sponsor
- University of Nebraska
- Primary completion
- Mar 2010
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Left Ventricular Ejection Fraction (LVEF) and Global Strain Decrease After Doxorubicin Chemotherapy |
5; 5 | — |
Summary
RATIONALE: Diagnostic procedures, such as cardiac magnetic resonance imaging, may help doctors detect early changes in the heart caused by chemotherapy.
PURPOSE: This clinical trial is studying how well cardiac magnetic resonance imaging works in patients with newly diagnosed non-Hodgkin lymphoma or Hodgkin lymphoma receiving doxorubicin.
Eligibility Criteria
Inclusion Criteria
- Diagnosis of non-Hodgkin lymphoma or Hodgkin lymphoma
o Newly diagnosed disease
- Planning to receive doxorubicin hydrochloride-based chemotherapy solely at the University of Nebraska Medical Center
- Fertile patients must use effective contraception
- Able to lie flat for 90 minutes
- Able to fulfill the requirements of the study
Exclusion Criteria
- Not pregnant or nursing
- No pacemaker
- No chronic kidney disease stages 3-5 (glomerular filtration rate < 60 mL/min)
- No metallic foreign body not approved for MRI
- No known hypersensitivity to gadolinium contrast or other required drugs in the study
- No comorbidity or condition which, in the opinion of the investigator, may interfere with the assessments and procedures of this study
- No prior chemotherapy
- No prior radiotherapy to mantle or mediastinum
Data sourced from ClinicalTrials.gov (NCT00577798). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.